Simcere Pharmaceutical Group Limited
SMHGF
$0.6697
-$0.0641-8.74%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.91% | -12.26% | -12.34% | -15.82% | 18.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.91% | -12.26% | -12.34% | -15.82% | 18.09% |
| Cost of Revenue | -23.14% | -24.31% | 2.96% | -1.13% | 38.75% |
| Gross Profit | -6.99% | -8.40% | -16.46% | -19.79% | 12.71% |
| SG&A Expenses | -10.92% | -12.27% | -18.73% | -21.97% | 18.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 9.55% | 10.91% | 21.69% | 24.81% | 17.27% |
| Total Operating Expenses | -19.01% | -20.24% | -16.69% | -20.01% | 22.89% |
| Operating Income | 57.54% | 55.16% | 53.11% | 47.02% | -11.24% |
| Income Before Tax | -79.40% | -79.72% | -287.11% | -279.67% | 4,071.57% |
| Income Tax Expenses | -28.21% | -29.30% | 20.02% | 23.20% | 615.01% |
| Earnings from Continuing Operations | -80.56% | -80.86% | -277.52% | -270.45% | 3,360.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -100.00% | -58.94% |
| Net Income | -80.57% | -80.86% | -277.05% | -270.01% | 3,260.38% |
| EBIT | 57.54% | 55.16% | 53.11% | 47.02% | -11.24% |
| EBITDA | 43.19% | 41.02% | 36.00% | 30.59% | -9.14% |
| EPS Basic | -79.97% | -80.28% | -278.54% | -271.07% | 3,157.89% |
| Normalized Basic EPS | 48.48% | 47.76% | 72.73% | 64.71% | -5.71% |
| EPS Diluted | -79.80% | -80.10% | -278.54% | -271.07% | 3,993.33% |
| Normalized Diluted EPS | 48.48% | 47.76% | 72.73% | 64.71% | -5.71% |
| Average Basic Shares Outstanding | -2.55% | -2.55% | -0.60% | -0.60% | 0.40% |
| Average Diluted Shares Outstanding | -2.95% | -2.95% | -0.93% | -0.93% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -1.60% | -1.60% | -- |